Hikma Pharmaceuticals plc
Company characteristics
| Assessed report publication year | |
|---|---|
| Financial year end | 31/12/23 |
| Sector | Health Care |
| Head office | United Kingdom |
| Primary listing | London Stock Exchange |
| GBP market cap | 3,955,145,727 |
| Net profit margin | 6.68% |
| CEO tenure | 0.3 years |
| Employee count | 8,967 |
| FRF draft assessment response |  |
Reward scrutiny
| Living wage accredited | |
Living wage (calculation for operating regions) |  |
|---|---|---|---|
| Living hours accredited | |
Tax reporting (GRI 207) | |
Remuneration policies
| Remuneration committee 100% independent | |
Remuneration committee discretion applied | |
|---|---|---|---|
| Remuneration committee discretion (direction) |  |
||
| Director from workforce | |
Trade union relations (disclosure) | |
| Worker consultation on top pay (disclosure) | |
80%+ shareholder support on pay | |
Reward outcomes
| CEO total pay (GBP) | 1,217,908 | CEO total pay change | -73.62% |
|---|---|---|---|
| CEO pay ratio (to median employee) | — | Percentage point increase in maximum variable remuneration | — |
| Pension award parity between CEO and wider workforce | |
Pay of the next highest exec compared to CEO | 182.91% |
| Gender pay gap (mean data) | N/A | Gender pay (women % in top quartile) | — |
| Ethnicity pay gap (disclosure) | |
Total dividend (USD) | 159,178,587 |